Validation of 3‐ and 5‐point severity scales to assess ARIA‐E

INTRODUCTION: Anti‐amyloid‐β (Aβ) monoclonal antibodies (mAbs) offer the promise of disease modification and are emerging treatment options in Alzheimer's disease. Anti‐Aβ mAbs require brain magnetic resonance imaging (MRI) examinations to detect anti‐amyloid‐induced amyloid‐related imaging abn...

Descripción completa

Detalles Bibliográficos
Autores principales: Bracoud, Luc, Klein, Gregory, Lyons, Marco, Scelsi, Marzia A., Wojtowicz, Jakub, Bullain, Szofia, Purcell, Derk, Fiebach, Jochen B., Barakos, Jerome, Suhy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667607/
https://www.ncbi.nlm.nih.gov/pubmed/38026755
http://dx.doi.org/10.1002/dad2.12503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667607/
https://www.ncbi.nlm.nih.gov/pubmed/38026755
http://dx.doi.org/10.1002/dad2.12503

Ejemplares similares